MedTrace Logo

Feasibility in the Prophylaxis of Radiation Dermatitis Severity

NCT04715386 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2024-02-09

No results posted yet for this study

Summary

To compare radiation dermatitis severity in irradiated skin protected by an agent verses uncovered skin based on photographs and track patient reported outcomes with use of the agent.

Conditions

  • Radiation Dermatitis

Interventions

DRUG

StrataXRT

Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.

Sponsors & Collaborators

Principal Investigators

  • Ivy Petersen, MD · Mayo Clinic Radiation Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2024-01-30
Completion
2024-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04715386 on ClinicalTrials.gov